8-K: Grace Therapeutics Reports Reduced Fiscal 2025 Net Loss, Advances Lead Drug GTx-104 Towards FDA Submission

Grace Therapeutics, Inc. announced a significant reduction in its fiscal year 2025 net loss, positive Phase 3 trial results for its lead drug GTx-104, and secured $15 million in upfront financing, with an NDA submission for GTx-104 expected by the end of June 2025.

Summary

• Grace Therapeutics reported a net loss of $9.6 million for the fiscal year ended March 31, 2025, a decrease from $12.9 million in the prior fiscal year.
• Loss per share improved to $0.79 from $1.35 in the previous fiscal year.
• The company successfully concluded its Phase 3 STRIVE-ON safety trial for GTx-104, an injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH), meeting its primary endpoint.
• GTx-104 demonstrated a 19% reduction in clinically significant hypotension compared to oral nimodipine (28% vs. 35%).
• The trial also showed 29% more patients on GTx-104 had favorable functional outcomes at 90 days and fewer ICU readmissions, ICU days, and ventilator days.
• Grace Therapeutics held a Type C meeting with the FDA and believes its data and regulatory packages are sufficient for the planned New Drug Application (NDA) submission for GTx-104.
• The NDA for GTx-104 is on track for submission to the FDA by the end of June 2025.
• The company secured $15 million in upfront gross proceeds from a private placement, with the potential for an additional $15 million from warrant exercises, totaling up to $30 million.
• Cash and cash equivalents stood at $22.1 million as of March 31, 2025, providing a cash runway into the third quarter of calendar 2026, potentially extending into the second quarter of calendar 2027 with warrant exercises.
• Development of GTx-101 has been deprioritized to focus on GTx-104, with potential for licensing or sale.

Sentiment

Score: 8

Explanation: The company reported a significant reduction in net loss and positive Phase 3 clinical trial results for its lead asset, GTx-104, which is on track for NDA submission. The successful capital raise provides a solid cash runway. While R&D and G&A expenses increased, this is tied to advancing the lead program. The deprioritization of GTx-101 is a minor negative but reflects strategic focus. The overall outlook is highly positive due to clinical and regulatory progress and strengthened financial position.

Positives

• Net loss decreased by $3.3 million to $9.6 million for fiscal year 2025, from $12.9 million in fiscal year 2024.
• Loss per share improved to $0.79 from $1.35.
• Successful conclusion of Phase 3 STRIVE-ON safety trial for GTx-104, meeting its primary endpoint.
• GTx-104 showed a 19% reduction in clinically significant hypotension compared to oral nimodipine (28% vs. 35%).
• GTx-104 demonstrated improved clinical outcomes, with 29% more patients having favorable functional outcomes at 90 days compared to oral nimodipine.
• Patients receiving GTx-104 experienced fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days.
• FDA feedback indicates that the data and regulatory packages for GTx-104 are believed to be sufficient for NDA submission.
• NDA for GTx-104 is on track for submission to the FDA by the end of June 2025.
• Secured $15 million in upfront gross proceeds from a private placement, with potential for an additional $15 million from warrant exercises.
• Current cash and cash equivalents provide a runway into Q3 calendar 2026, potentially extending to Q2 calendar 2027 with full warrant exercise.
• GTx-104 and GTx-102 have received Orphan Drug Designation from the FDA, providing seven years of marketing exclusivity post-launch.

Negatives

• Research and development expenses increased by $4.8 million to $9.5 million for fiscal year 2025, primarily due to the GTx-104 Phase 3 trial.
• General and administrative expenses increased by $0.5 million to $7.2 million, due to increased legal, tax, accounting, and professional fees, and higher salaries and benefits.
• Cash and cash equivalents decreased slightly by $0.9 million to $22.1 million as of March 31, 2025, compared to $23.0 million at March 31, 2024.
• The STRIVE-ON trial, while positive, was not designed or powered to demonstrate efficacy, and there were more deaths in the GTx-104 arm (8 deaths) compared to the oral nimodipine arm (4 deaths), though none were determined to be drug-related.
• Development of GTx-101 has been deprioritized, indicating a reduction in the company's pipeline focus.

Risks

• The success and timing of regulatory submissions of the Phase 3 STRIVE-ON safety trial for GTx-104.
• Regulatory requirements or developments and the outcome and timing of the proposed NDA application for GTx-104.
• Changes to regulatory pathways.
• Legislative, regulatory, political, and economic developments.
• Actual results and the timing of events could differ materially from forward-looking statements due to various risks and uncertainties.
• The company's cash runway is dependent on the exercise of warrants, which is at the election of investors.

Future Outlook

Grace Therapeutics expects to finalize and submit its New Drug Application (NDA) for GTx-104 to the FDA by the end of June 2025, based on positive Phase 3 STRIVE-ON trial data and favorable FDA feedback. The company anticipates its current cash and cash equivalents will provide a runway into the third quarter of calendar 2026, with potential extension into the second quarter of calendar 2027 if all outstanding warrants are exercised. The company also plans to advance GTx-102 towards a pivotal efficacy and safety trial following FDA guidance, while potentially licensing or selling GTx-101 to focus resources on GTx-104.

Management Comments

• "During our 2025 fiscal year we made significant progress in both clinical and corporate goals, led by our announcement of positive topline data from our Phase 3 STRIVE-ON safety trial and alignment with the U.S. Food and Drug Administration (FDA) on our planned submission of an NDA for GTx-104 for the treatment of aSAH." Prashant Kohli, CEO.
• "We also secured financing of $15 million up front with the potential to receive up to an additional $15 million upon cash exercise of accompanying warrants... This investment will support pre-commercial planning, commercial team build out and product launch, if GTx-104 is approved." Prashant Kohli, CEO.
• "Our focus now is to finalize our NDA submission for GTx-104, which we expect to complete by the end of June 2025." Prashant Kohli, CEO.
• "The standard of care for aSAH has not seen meaningful innovation in nearly 40 years. Data from our STRIVE-ON trial exceeded our expectations, and although STRIVE-ON was not designed or powered to demonstrate efficacy, the data provide support for improved clinical outcomes for patients treated with GTx-104 when compared to patients treated with orally administered nimodipine." Prashant Kohli, CEO.
• "Importantly, the data also provides both medical and pharmacoeconomic evidence of the potential benefit of GTx-104 in aSAH patients, which could help drive adoption of GTx-104 by neurocritical care physicians and hospital pharmacies." Prashant Kohli, CEO.
• "We believe the STRIVE-ON trial results point to a very promising role for GTx-104 as a potential breakthrough for the care of aSAH patients should it be approved by the FDA." Prashant Kohli, CEO.

Industry Context

The announcement highlights Grace Therapeutics' efforts to innovate in the treatment of aneurysmal subarachnoid hemorrhage (aSAH), a condition where the standard of care (oral nimodipine) has seen little innovation in nearly 40 years. GTx-104, an injectable formulation, aims to address significant unmet medical needs by offering a more convenient IV delivery, potentially eliminating the need for nasogastric tube administration, and improving management of hypotension compared to the current oral standard. This positions Grace Therapeutics as a potential disruptor in a niche but critical neurocritical care market, aiming to provide a breakthrough for aSAH patients.

Comparison to Industry Standards

• GTx-104 is compared directly to the current standard of care for aSAH, orally administered nimodipine.
• GTx-104 demonstrated a 19% reduction in clinically significant hypotension compared to oral nimodipine (28% versus 35%).
• 54% of patients on GTx-104 had a relative dose intensity (RDI) of 95% or higher, significantly better than only 8% on oral nimodipine.
• 29% more patients treated with GTx-104 had favorable functional outcomes at 90 days compared to those on oral nimodipine.
• GTx-104 also led to fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days compared to oral nimodipine.
• For Postherpetic Neuralgia (PHN), GTx-101 is mentioned as an alternative to oral gabapentin and lidocaine patches, with the company believing its biphasic delivery mechanism could offer rapid onset and continuous pain relief for up to eight hours.

Stakeholder Impact

• Shareholders: Positive impact due to reduced net loss, successful Phase 3 trial results for lead asset, secured financing, and clear path to NDA submission, potentially increasing company valuation and future revenue prospects.
• Patients (aSAH): Potential for a new, improved treatment option (GTx-104) that could lead to better clinical outcomes, reduced complications, and more convenient administration compared to current standard of care.
• Healthcare Providers (Neurocritical Care Physicians, Hospital Pharmacies): GTx-104 could offer a more effective and manageable treatment for aSAH, potentially driving adoption due to medical and pharmacoeconomic benefits.
• Employees: Continued employment and potential growth opportunities as the company moves towards commercialization of GTx-104.
• Creditors/Investors: Strengthened financial position and clear development milestones may increase confidence.

Next Steps

• Finalize and submit the New Drug Application (NDA) for GTx-104 to the FDA by the end of June 2025.
• Support pre-commercial planning, commercial team build-out, and product launch for GTx-104, if approved.
• Design and potentially initiate a single pivotal efficacy and safety trial for GTx-102 based on FDA guidance.
• Potentially license or sell GTx-101.

Key Dates

Recommendation

Keywords

Grace Therapeutics, GRCE, SEC Filing, 8-K, Financial Results, Biopharma, Clinical Trials, GTx-104, aSAH, Aneurysmal Subarachnoid Hemorrhage, Nimodipine, FDA, NDA Submission, STRIVE-ON Trial, Phase 3, Private Placement, Capital Raise, Orphan Drug, GTx-102, Ataxia-Telangiectasia, GTx-101, Postherpetic Neuralgia, Drug Development, Biotechnology, Pharmaceuticals